Annual SGA
$59.54 M
+$2.58 M+4.53%
December 31, 2023
Summary
- As of February 8, 2025, MRSN annual SGA is $59.54 million, with the most recent change of +$2.58 million (+4.53%) on December 31, 2023.
- During the last 3 years, MRSN annual SGA has risen by +$37.64 million (+171.86%).
- MRSN annual SGA is now at all-time high.
Performance
MRSN SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly SGA
$9.86 M
-$639.00 K-6.08%
September 30, 2024
Summary
- As of February 8, 2025, MRSN quarterly SGA is $9.86 million, with the most recent change of -$639.00 thousand (-6.08%) on September 30, 2024.
- Over the past year, MRSN quarterly SGA has dropped by -$3.03 million (-23.50%).
- MRSN quarterly SGA is now -46.18% below its all-time high of $18.33 million, reached on March 31, 2023.
Performance
MRSN Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM SGA
-$3.42 B
-$74.62 M-2.23%
September 30, 2024
Summary
- As of February 8, 2025, MRSN TTM SGA is -$3.42 billion, with the most recent change of -$74.62 million (-2.23%) on September 30, 2024.
- Over the past year, MRSN TTM SGA has dropped by -$3.49 billion (-5431.23%).
- MRSN TTM SGA is now -5685.60% below its all-time high of -$59.17 million.
Performance
MRSN TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
MRSN Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +4.5% | -23.5% | -5431.2% |
| 3 y3 years | +171.9% | -23.5% | -5431.2% |
| 5 y5 years | +264.5% | -23.5% | -5431.2% |
MRSN Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +61.4% | -46.2% | at low | -124.8% | at low |
| 5 y | 5-year | at high | +244.5% | -46.2% | +134.2% | -410.9% | at low |
| alltime | all time | at high | +1013.6% | -46.2% | +517.3% | -5685.6% | at low |
Mersana Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $9.86 M(-6.1%) | $42.06 M(-6.7%) |
| Jun 2024 | - | $10.50 M(-9.1%) | $45.09 M(-14.6%) |
| Mar 2024 | - | $11.56 M(+14.1%) | $52.77 M(-11.4%) |
| Dec 2023 | $59.54 M(+4.5%) | $10.13 M(-21.4%) | $59.54 M(-7.3%) |
| Sep 2023 | - | $12.89 M(-29.1%) | $64.21 M(-2.5%) |
| Jun 2023 | - | $18.19 M(-0.8%) | $65.89 M(+5.4%) |
| Mar 2023 | - | $18.33 M(+23.8%) | $62.51 M(+9.7%) |
| Dec 2022 | $56.96 M(+54.4%) | $14.80 M(+1.6%) | $56.96 M(+7.8%) |
| Sep 2022 | - | $14.57 M(-1.6%) | $52.83 M(+9.2%) |
| Jun 2022 | - | $14.80 M(+15.8%) | $48.38 M(+13.9%) |
| Mar 2022 | - | $12.78 M(+19.7%) | $42.46 M(+15.1%) |
| Dec 2021 | $36.89 M(+68.4%) | $10.67 M(+5.4%) | $36.89 M(+14.8%) |
| Sep 2021 | - | $10.12 M(+14.0%) | $32.13 M(+15.2%) |
| Jun 2021 | - | $8.88 M(+23.2%) | $27.89 M(+15.4%) |
| Mar 2021 | - | $7.21 M(+21.9%) | $24.17 M(+10.4%) |
| Dec 2020 | $21.90 M | $5.91 M(+0.6%) | $21.90 M(+8.4%) |
| Sep 2020 | - | $5.88 M(+13.7%) | $20.20 M(+7.7%) |
| Jun 2020 | - | $5.17 M(+4.8%) | $18.75 M(+5.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | $4.94 M(+17.2%) | $17.77 M(+2.9%) |
| Dec 2019 | $17.28 M(+5.8%) | $4.21 M(-5.1%) | $17.28 M(+0.3%) |
| Sep 2019 | - | $4.44 M(+5.8%) | $17.22 M(+0.3%) |
| Jun 2019 | - | $4.19 M(-5.6%) | $17.17 M(-0.2%) |
| Mar 2019 | - | $4.44 M(+7.0%) | $17.21 M(+5.3%) |
| Dec 2018 | $16.33 M(+56.1%) | $4.15 M(-5.2%) | $16.34 M(+7.2%) |
| Sep 2018 | - | $4.38 M(+3.5%) | $15.24 M(+10.7%) |
| Jun 2018 | - | $4.23 M(+18.5%) | $13.76 M(+17.3%) |
| Mar 2018 | - | $3.57 M(+16.9%) | $11.74 M(+12.2%) |
| Dec 2017 | $10.46 M(+49.8%) | $3.06 M(+5.2%) | $10.46 M(+11.9%) |
| Sep 2017 | - | $2.90 M(+31.8%) | $9.35 M(+16.3%) |
| Jun 2017 | - | $2.20 M(-4.0%) | $8.04 M(+4.9%) |
| Mar 2017 | - | $2.30 M(+18.4%) | $7.66 M(+9.7%) |
| Dec 2016 | $6.98 M(+30.6%) | $1.94 M(+21.4%) | $6.99 M(+38.5%) |
| Sep 2016 | - | $1.60 M(-12.5%) | $5.04 M(+46.4%) |
| Jun 2016 | - | $1.83 M(+12.6%) | $3.45 M(+112.6%) |
| Mar 2016 | - | $1.62 M | $1.62 M |
| Dec 2015 | $5.35 M | - | - |
FAQ
- What is Mersana Therapeutics annual SGA?
- What is the all time high annual SGA for Mersana Therapeutics?
- What is Mersana Therapeutics annual SGA year-on-year change?
- What is Mersana Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Mersana Therapeutics?
- What is Mersana Therapeutics quarterly SGA year-on-year change?
- What is Mersana Therapeutics TTM SGA?
- What is the all time high TTM SGA for Mersana Therapeutics?
- What is Mersana Therapeutics TTM SGA year-on-year change?
What is Mersana Therapeutics annual SGA?
The current annual SGA of MRSN is $59.54 M
What is the all time high annual SGA for Mersana Therapeutics?
Mersana Therapeutics all-time high annual SGA is $59.54 M
What is Mersana Therapeutics annual SGA year-on-year change?
Over the past year, MRSN annual SGA has changed by +$2.58 M (+4.53%)
What is Mersana Therapeutics quarterly SGA?
The current quarterly SGA of MRSN is $9.86 M
What is the all time high quarterly SGA for Mersana Therapeutics?
Mersana Therapeutics all-time high quarterly SGA is $18.33 M
What is Mersana Therapeutics quarterly SGA year-on-year change?
Over the past year, MRSN quarterly SGA has changed by -$3.03 M (-23.50%)
What is Mersana Therapeutics TTM SGA?
The current TTM SGA of MRSN is -$3.42 B
What is the all time high TTM SGA for Mersana Therapeutics?
Mersana Therapeutics all-time high TTM SGA is -$59.17 M
What is Mersana Therapeutics TTM SGA year-on-year change?
Over the past year, MRSN TTM SGA has changed by -$3.49 B (-5431.23%)